| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England journal of medicine 359 (4), 378-390, 2008 | 15683 | 2008 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 6641 | 2017 |
| IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer FR Greten, L Eckmann, TF Greten, JM Park, ZW Li, LJ Egan, MF Kagnoff, ... Cell 118 (3), 285-296, 2004 | 3287 | 2004 |
| Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards V Bronte, S Brandau, SH Chen, MP Colombo, AB Frey, TF Greten, ... Nature communications 7 (1), 12150, 2016 | 2748 | 2016 |
| EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma EO for Research, European Association for the Study of the Liver Journal of hepatology 56 (4), 908-943, 2012 | 1883 | 2012 |
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study J Lammer, K Malagari, T Vogl, F Pilleul, A Denys, A Watkinson, M Pitton, ... Cardiovascular and interventional radiology 33, 41-52, 2010 | 1865 | 2010 |
| Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells C Ma, M Han, B Heinrich, Q Fu, Q Zhang, M Sandhu, D Agdashian, ... Science 360 (6391), eaan5931, 2018 | 1299 | 2018 |
| A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells B Hoechst, LA Ormandy, M Ballmaier, F Lehner, C Krüger, MP Manns, ... Gastroenterology 135 (1), 234-243, 2008 | 980 | 2008 |
| Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma LA Ormandy, T Hillemann, H Wedemeyer, MP Manns, TF Greten, ... Cancer research 65 (6), 2457-2464, 2005 | 922 | 2005 |
| Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma AG Duffy, SV Ulahannan, O Makorova-Rusher, O Rahma, H Wedemeyer, ... Journal of hepatology 66 (3), 545-551, 2017 | 833 | 2017 |
| Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor B Hoechst, T Voigtlaender, L Ormandy, J Gamrekelashvili, F Zhao, ... Hepatology 50 (3), 799-807, 2009 | 734 | 2009 |
| Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma JM Llovet, T De Baere, L Kulik, PK Haber, TF Greten, T Meyer, R Lencioni Nature reviews Gastroenterology & hepatology 18 (5), 293-313, 2021 | 730 | 2021 |
| NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis C Ma, AH Kesarwala, T Eggert, J Medina-Echeverz, DE Kleiner, P Jin, ... Nature 531 (7593), 253-257, 2016 | 705 | 2016 |
| Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer DT Le, A Wang-Gillam, V Picozzi, TF Greten, T Crocenzi, G Springett, ... Journal of clinical oncology 33 (12), 1325-1333, 2015 | 696 | 2015 |
| Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer L Ma, MO Hernandez, Y Zhao, M Mehta, B Tran, M Kelly, Z Rae, ... Cancer cell 36 (4), 418-430. e6, 2019 | 625 | 2019 |
| Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression T Eggert, K Wolter, J Ji, C Ma, T Yevsa, S Klotz, J Medina-Echeverz, ... Cancer cell 30 (4), 533-547, 2016 | 574 | 2016 |
| Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial H Oettle, H Riess, JM Stieler, G Heil, I Schwaner, J Seraphin, M Görner, ... Journal of Clinical Oncology 32 (23), 2423-2429, 2014 | 558 | 2014 |
| Myeloid derived suppressor cells in human diseases TF Greten, MP Manns, F Korangy International immunopharmacology 11 (7), 802-807, 2011 | 535 | 2011 |
| Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial D Malka, P Cervera, S Foulon, T Trarbach, C de la Fouchardière, ... The lancet oncology 15 (8), 819-828, 2014 | 438 | 2014 |
| Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway LA Haile, R Von Wasielewski, J Gamrekelashvili, C Krüger, O Bachmann, ... Gastroenterology 135 (3), 871-881. e5, 2008 | 384 | 2008 |
Bradford J. WoodNational Institutes of HealthEmail yang diverifikasi di nih.gov